Sugi Predict

Sugi Predict / Compounds / SCHEMBL5745010

SCHEMBL5745010

SCHEMBL5745010

CC(C)(C)OC(=O)NCCc1c[nH]c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.67
▸ KMT2A Q03164 5/20 0.67
▸ FAAH O00519 2/20 0.67
▸ LMNA P02545 1/20 0.67
▸ CYP1A2 P05177 1/20 0.67
▸ PKM P14618 1/20 0.67
▸ TSHR P16473 1/20 0.67
▸ CYP2C19 P33261 1/20 0.67
▸ BLM P54132 1/20 0.67
▸ NPC1 O15118 2/20 0.61
▸ RAB9A P51151 2/20 0.61
▸ MMP9 P14780 1/20 0.61
▸ AANAT Q16613 1/20 0.61
▸ CDK4 P11802 1/20 0.60
▸ CCND1 P24385 1/20 0.60
▸ SIRT1 Q96EB6 2/20 0.59
▸ MTNR1A P48039 1/20 0.59
▸ POLB P06746 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7846607 0.93 FAAH (0.58) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL32678237 0.92 MEN1 (0.62) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL32678233 0.92 MEN1 (0.62) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL22039141 0.89 MAPT (0.61) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL30561257 0.89 MAPT (0.61) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL22039146 0.87 FAAH (0.53) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL22038251 0.87 MEN1 (0.61) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL30561254 0.87 MEN1 (0.61) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL19100705 0.87 CTSL (0.58) MEN1KMT2AFAAHLMNACYP1A2
SCHEMBL20927525 0.87 MEN1 (0.74) MEN1KMT2AFAAHLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079853-A N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases — 2026-05-26 — — CN disclosed
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250382266-A1 5-HT2A RECEPTOR LIGANDS PSILERA INC (US) 2025-12-18 — — US disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-117903036-A Synthesis and application of novel FXR (FXR) agonist 厦门市博瑞来医药科技有限公司 2024-04-19 — — CN disclosed
CN-117106007-B Loose lupeane derivative and application thereof in preparation of multi-target tumor angiogenesis and invasion metastasis inhibitor 吉林农业大学 2024-03-19 — — CN disclosed
CN-117106007-A Loose lupeane derivative and application thereof in preparation of multi-target tumor angiogenesis and invasion metastasis inhibitor 吉林农业大学 2023-11-24 — — CN disclosed
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 — — US disclosed
US-6872827-B2 Somatostatin analogue compounds CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2005-03-29 — — US disclosed
US-20040019069-A1 Somatostatin analogue compounds CHEMBRIDGE CORPORATION 2004-01-29 — — US disclosed
WO-2003090677-A2 SOMATOSTATIN ANALOGUE COMPOUNDS CHEMBRIDGE RESEARCH LAB., LLC (US) 2003-11-06 — — WO disclosed
US-5952326-A Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases PFIZER INC. (US) 1999-09-14 — — US disclosed
US-5698550-A Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases PFIZER INC. (US) 1997-12-16 — — US disclosed
EP-0693081-A1 CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION Novartis AG (CH) 1996-01-24 — — EP disclosed
EP-0441515-B1 Tetralin and chroman derivatives in the treatment of asthma, arthritis and related diseases PFIZER (US) 1995-10-04 — — EP disclosed
WO-1994024153-A1 CYCLIC COMPOUNDS AND COMPOSITIONS WHICH INHIBIT BONE RESORPTION CIBA-GEIGY AG (CH) 1994-10-27 — — WO disclosed
WO-1991012253-A1 TETRALIN AND CHROMAN DERIVATIVES USEFUL IN THE TREATMENT OF ASTHMA, ARTHRITIS, AND RELATED DISEASES PFIZER INC. (US) 1991-08-22 — — WO disclosed
EP-0441515-A1 Tetralin and chroman derivatives in the treatment of asthma, arthritis and related diseases PFIZER INC. (US) 1991-08-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382266-A1 5-HT2A RECEPTOR LIGANDS HTR2A, HTR2C, HTR5A MEN1 3703/4885KMT2A 617/4885FAAH 404/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 MEN1 4767/4885KMT2A 622/4885FAAH 102/4885
US-11787783-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE MEN1 3249/4885KMT2A 3905/4885FAAH 1225/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 MEN1 4767/4885KMT2A 622/4885FAAH 102/4885
US-20040019069-A1 Somatostatin analogue compounds SSTR2, SSTR1, SSTR4 MEN1 198/4885KMT2A 1844/4885FAAH 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.